1
|
High-throughput optical assays for sensing serine hydrolases in living systems and their applications. Trends Analyt Chem 2022. [DOI: 10.1016/j.trac.2022.116620] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
2
|
Still KB, Slagboom J, Kidwai S, Xie C, Zhao Y, Eisses B, Jiang Z, Vonk FJ, Somsen GW, Casewell NR, Kool J. Development of high-throughput screening assays for profiling snake venom phospholipase A2 activity after chromatographic fractionation. Toxicon 2020; 184:28-38. [DOI: 10.1016/j.toxicon.2020.05.022] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Revised: 05/26/2020] [Accepted: 05/27/2020] [Indexed: 10/24/2022]
|
3
|
Aggarwal G, Zarrow JE, Mashhadi Z, Flynn CR, Vinson P, Weaver CD, Davies SS. Symmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D. J Biol Chem 2020; 295:7289-7300. [PMID: 32284327 PMCID: PMC7247316 DOI: 10.1074/jbc.ra120.013362] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 04/06/2020] [Indexed: 01/09/2023] Open
Abstract
N-Acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD) (EC 3.1.4.4) catalyzes the final step in the biosynthesis of N-acyl-ethanolamides. Reduced NAPE-PLD expression and activity may contribute to obesity and inflammation, but a lack of effective NAPE-PLD inhibitors has been a major obstacle to elucidating the role of NAPE-PLD and N-acyl-ethanolamide biosynthesis in these processes. The endogenous bile acid lithocholic acid (LCA) inhibits NAPE-PLD activity (with an IC50 of 68 μm), but LCA is also a highly potent ligand for TGR5 (EC50 0.52 μm). Recently, the first selective small-molecule inhibitor of NAPE-PLD, ARN19874, has been reported (having an IC50 of 34 μm). To identify more potent inhibitors of NAPE-PLD, here we used a quenched fluorescent NAPE analog, PED-A1, as a substrate for recombinant mouse Nape-pld to screen a panel of bile acids and a library of experimental compounds (the Spectrum Collection). Muricholic acids and several other bile acids inhibited Nape-pld with potency similar to that of LCA. We identified 14 potent Nape-pld inhibitors in the Spectrum Collection, with the two most potent (IC50 = ∼2 μm) being symmetrically substituted dichlorophenes, i.e. hexachlorophene and bithionol. Structure-activity relationship assays using additional substituted dichlorophenes identified key moieties needed for Nape-pld inhibition. Both hexachlorophene and bithionol exhibited significant selectivity for Nape-pld compared with nontarget lipase activities such as Streptomyces chromofuscus PLD or serum lipase. Both also effectively inhibited NAPE-PLD activity in cultured HEK293 cells. We conclude that symmetrically substituted dichlorophenes potently inhibit NAPE-PLD in cultured cells and have significant selectivity for NAPE-PLD versus other tissue-associated lipases.
Collapse
Affiliation(s)
- Geetika Aggarwal
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232
| | - Jonah E Zarrow
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232
| | - Zahra Mashhadi
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232
| | - C Robb Flynn
- Division of Surgery, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232
| | - Paige Vinson
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232; Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232
| | - C David Weaver
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232
| | - Sean S Davies
- Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232; Vanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232; Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232.
| |
Collapse
|
4
|
El Alaoui M, Soulère L, Noiriel A, Popowycz F, Khatib A, Queneau Y, Abousalham A. A continuous spectrophotometric assay that distinguishes between phospholipase A1 and A2 activities. J Lipid Res 2016; 57:1589-97. [PMID: 27194811 PMCID: PMC4959851 DOI: 10.1194/jlr.d065961] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 05/11/2016] [Indexed: 11/30/2022] Open
Abstract
A new spectrophotometric assay was developed to measure, continuously and specifically, phospholipase A1 (PLA1) or phospholipase A2 (PLA2) activities using synthetic glycerophosphatidylcholines (PCs) containing α-eleostearic acid, either at the sn-1 position [1-α-eleostearoyl-2-octadecyl-rac-glycero-3-phosphocholine (EOPC)] or at the sn-2 position [1-octadecyl-2-α-eleostearoyl-rac-glycero-3-phosphocholine (OEPC)]. The substrates were coated onto the wells of microtiter plates. A nonhydrolyzable ether bond, with a non-UV-absorbing alkyl chain, was introduced at the other sn position to prevent acyl chain migration during lipolysis. Upon enzyme action, α-eleostearic acid is liberated and then solubilized into the micellar phase. The PLA1 or PLA2 activity was measured by the increase in absorbance at 272 nm due to the transition of α-eleostearic acid from the adsorbed to the soluble state. EOPC and OEPC differentiate, with excellent accuracy, between PLA1 and PLA2 activity. Lecitase(®), guinea pig pancreatic lipase-related protein 2 (known to be a PLA1 enzyme), bee venom PLA2, and porcine pancreatic PLA2 were all used to validate the assay. Compared with current assays used for continuously measuring PLA1 or PLA2 activities and/or their inhibitors, the development of this sensitive enzymatic method, using coated PC substrate analogs to natural lipids and based on the UV spectroscopic properties of α-eleostearic acid, is a significant improvement.
Collapse
Affiliation(s)
- Meddy El Alaoui
- Univ Lyon, Université Lyon 1, UMR 5246, CNRS, INSA Lyon, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Métabolismes, Enzymes et Mécanismes Moléculaires (MEM), F-69622 Villeurbanne, France Univ Lyon, INSA Lyon, UMR 5246, CNRS, Université Lyon 1, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Chimie Organique et Bioorganique (COB), F-69621 Villeurbanne, France
| | - Laurent Soulère
- Univ Lyon, INSA Lyon, UMR 5246, CNRS, Université Lyon 1, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Chimie Organique et Bioorganique (COB), F-69621 Villeurbanne, France
| | - Alexandre Noiriel
- Univ Lyon, Université Lyon 1, UMR 5246, CNRS, INSA Lyon, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Métabolismes, Enzymes et Mécanismes Moléculaires (MEM), F-69622 Villeurbanne, France
| | - Florence Popowycz
- Univ Lyon, INSA Lyon, UMR 5246, CNRS, Université Lyon 1, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Chimie Organique et Bioorganique (COB), F-69621 Villeurbanne, France
| | - Abdallah Khatib
- Univ Lyon, Université Lyon 1, UMR 5246, CNRS, INSA Lyon, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Métabolismes, Enzymes et Mécanismes Moléculaires (MEM), F-69622 Villeurbanne, France
| | - Yves Queneau
- Univ Lyon, INSA Lyon, UMR 5246, CNRS, Université Lyon 1, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Chimie Organique et Bioorganique (COB), F-69621 Villeurbanne, France
| | - Abdelkarim Abousalham
- Univ Lyon, Université Lyon 1, UMR 5246, CNRS, INSA Lyon, CPE Lyon, Institut de Chimie et de Biochimie Moléculaires et Supramoléculaires (ICBMS), Métabolismes, Enzymes et Mécanismes Moléculaires (MEM), F-69622 Villeurbanne, France
| |
Collapse
|
5
|
Papillon JPN, Pan M, Brousseau ME, Gilchrist MA, Lou C, Singh AK, Stawicki T, Thompson JE. Synthetic phospholipids as specific substrates for plasma endothelial lipase. Bioorg Med Chem Lett 2016; 26:3514-7. [PMID: 27344207 DOI: 10.1016/j.bmcl.2016.06.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2016] [Revised: 06/10/2016] [Accepted: 06/11/2016] [Indexed: 11/25/2022]
Abstract
We designed and prepared synthetic phospholipids that generate lyso-phosphatidylcholine products with a unique mass for convenient detection by LC-MS in complex biological matrices. We demonstrated that compound 4, formulated either as a Triton X-100 emulsion or incorporated in synthetic HDL particles can serve as a substrate for plasma EL with useful specificity.
Collapse
Affiliation(s)
- Julien P N Papillon
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, United States.
| | - Meihui Pan
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, United States.
| | - Margaret E Brousseau
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, United States
| | - Mark A Gilchrist
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, United States
| | - Changgang Lou
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, United States
| | - Alok K Singh
- Global Discovery Chemistry, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, United States
| | - Todd Stawicki
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, United States
| | - James E Thompson
- Cardiovascular and Metabolism, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139, United States
| |
Collapse
|
6
|
Andersen RJ, Brask J. Synthesis and evaluation of fluorogenic triglycerides as lipase assay substrates. Chem Phys Lipids 2016; 198:72-9. [DOI: 10.1016/j.chemphyslip.2016.05.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 05/23/2016] [Accepted: 05/25/2016] [Indexed: 10/21/2022]
|
7
|
Sun L, Ishida T, Miyashita K, Kinoshita N, Mori K, Yasuda T, Toh R, Nakajima K, Imamura S, Hirata KI. Plasma activity of endothelial lipase impacts high-density lipoprotein metabolism and coronary risk factors in humans. J Atheroscler Thromb 2013; 21:313-21. [PMID: 24369272 DOI: 10.5551/jat.20131] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
AIM Endothelial lipase (EL) is a determinant of plasma levels of high-density lipoprotein cholesterol (HDL-C). However, little is known about the impact of EL activity on plasma lipid profile. We aimed to establish a new method to evaluate EL-specific phospholipase activity in humans. METHODS Plasma samples were obtained from 115 patients with coronary artery disease (CAD) and 154 patients without CAD. Plasma EL protein was immunoprecipitated using an anti-EL monoclonal antibody after plasma non-specific immunoglobulins were removed by incubation with ProteinA. The phospholipase activity of the immunoprecipitated samples was measured using a fluorogenic phospholipase substrate, Bis-BODIPY FL C11-PC. RESULTS The EL-specific phospholipase assay revealed that plasma EL activity was inversely correlated with HDL-C levels (R = -0.3088, p<0.0001). In addition, the EL activity was associated with cigarette smoking. Furthermore, EL activity in CAD patients was significantly higher than that in nonCAD patients. Concomitantly, the HDL-C level in CAD patients were significantly lower than that in non-CAD patients. CONCLUSION We have established a method for human plasma EL-specific phospholipase activity by combination of EL immunoprecipitation and a fluorogenic phospholipid substrate. Plasma EL activity was associated with not only plasma HDL-C levels but also the risks for CAD.
Collapse
Affiliation(s)
- Li Sun
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Sun S, Dean R, Jia Q, Zenova A, Zhong J, Grayson C, Xie C, Lindgren A, Samra P, Sojo L, van Heek M, Lin L, Percival D, Fu JM, Winther MD, Zhang Z. Discovery of XEN445: a potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice. Bioorg Med Chem 2013; 21:7724-34. [PMID: 24211162 DOI: 10.1016/j.bmc.2013.10.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2013] [Revised: 10/08/2013] [Accepted: 10/17/2013] [Indexed: 10/26/2022]
Abstract
Endothelial lipase (EL) activity has been implicated in HDL metabolism and in atherosclerotic plaque development; inhibitors are proposed to be efficacious in the treatment of dyslipidemia related cardiovascular disease. We describe here the discovery of a novel class of anthranilic acids EL inhibitors. XEN445 (compound 13) was identified as a potent and selective EL inhibitor, that showed good ADME and PK properties, and demonstrated in vivo efficacy in raising plasma HDLc concentrations in mice.
Collapse
Affiliation(s)
- Shaoyi Sun
- Xenon Pharmaceuticals Inc, 200-3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Razzaghi H, Tempczyk-Russell A, Haubold K, Santorico SA, Shokati T, Christians U, Churchill MEA. Genetic and structure-function studies of missense mutations in human endothelial lipase. PLoS One 2013; 8:e55716. [PMID: 23536757 PMCID: PMC3607615 DOI: 10.1371/journal.pone.0055716] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2012] [Accepted: 12/29/2012] [Indexed: 11/18/2022] Open
Abstract
Endothelial lipase (EL) plays a pivotal role in HDL metabolism. We sought to characterize EL and its interaction with HDL as well as its natural variants genetically, functionally and structurally. We screened our biethnic population sample (n = 802) for selected missense mutations (n = 5) and identified T111I as the only common variant. Multiple linear regression analyses in Hispanic subjects revealed an unexpected association between T111I and elevated LDL-C (p-value = 0.012) and total cholesterol (p-value = 0.004). We examined lipase activity of selected missense mutants (n = 10) and found different impacts on EL function, ranging from normal to complete loss of activity. EL-HDL lipidomic analyses indicated that EL has a defined remodeling of HDL without exhaustion of the substrate and a distinct and preference for several fatty acids that are lipid mediators and known for their potent pro- and anti-inflammatory properties. Structural studies using homology modeling revealed a novel α/β motif in the C-domain, unique to EL. The EL dimer was found to have the flexibility to expand and to bind various sizes of HDL particles. The likely impact of the all known missense mutations (n = 18) on the structure of EL was examined using molecular modeling and the impact they may have on EL lipase activity using a novel structure-function slope based on their structural free energy differences. The results of this multidisciplinary approach delineated the impact of EL and its variants on HDL. Moreover, the results suggested EL to have the capacity to modulate vascular health through its role in fatty acid-based signaling pathways.
Collapse
Affiliation(s)
- Hamid Razzaghi
- Division of Cardiology, Department of Medicine, University of Colorado Denver, Aurora, Colorado, United States of America.
| | | | | | | | | | | | | |
Collapse
|
10
|
Hanada H, Kobuchi H, Yamamoto M, Kashiwagi K, Katsu K, Utsumi T, Kashiwagi A, Sasaki J, Inoue M, Utsumi K. Acetyl-L-carnitine suppresses thyroid hormone-induced and spontaneous anuran tadpole tail shortening. Hereditas 2013; 150:1-9. [PMID: 23489246 DOI: 10.1111/j.1601-5223.2013.02284.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Mitochondrial membrane permeability transition (MPT) plays a crucial role in apoptotic tail shortening during anuran metamorphosis. L-carnitine is known to shuttle free fatty acids (FFAs) from the cytosol into mitochondria matrix for β-oxidation and energy production, and in a previous study we found that treatment with L-carnitine suppresses 3, 3', 5-triiodothyronine (T3 ) and FFA-induced MPT by reducing the level of FFAs. In the present study we focus on acetyl-L-carnitine, which is also involved in fatty acid oxidation, to determine its effect on T3 -induced tail regression in Rana rugosa tadpoles and spontaneous tail regression in Xenopus laevis tadpoles. The ladder-like DNA profile and increases in caspase-3 and caspase-9 indicative of apoptosis in the tails of T3 -treated tadpoles were found to be suppressed by the addition of acetyl-L-carnitine. Likewise, acetyl-L-carnitine was found to inhibit thyroid hormone regulated spontaneous metamorphosis in X. laevis tadpoles, accompanied by decreases in caspase and phospholipase A2 activity, as well as non-ladder-like DNA profiles. These findings support our previous conclusion that elevated levels of FFAs initiate MPT and activate the signaling pathway controlling apoptotic cell death in tadpole tails during anuran metamorphosis.
Collapse
Affiliation(s)
- Hideki Hanada
- Institute for Amphibian Biology, Graduate School of Science, Hiroshima University, Higashihiroshima, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
The chemistry of small-molecule fluorogenic probes. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2013; 113:1-34. [PMID: 23244787 DOI: 10.1016/b978-0-12-386932-6.00001-6] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
Chemical fluorophores find wide use in biology to detect and visualize different phenomena. A key advantage of small-molecule dyes is the ability to construct compounds where fluorescence is activated by chemical or biochemical processes. Fluorogenic molecules, in which fluorescence is activated by enzymatic activity, light, or environmental changes, enable advanced bioassays and sophisticated imaging experiments. Here, we detail the collection of fluorophores and highlight both general strategies and unique approaches that are employed to control fluorescence using chemistry.
Collapse
|
12
|
Singaraja RR, Sivapalaratnam S, Hovingh K, Dubé MP, Castro-Perez J, Collins HL, Adelman SJ, Riwanto M, Manz J, Hubbard B, Tietjen I, Wong K, Mitnaul LJ, van Heek M, Lin L, Roddy TA, McEwen J, Dallinge-Thie G, van Vark-van der Zee L, Verwoert G, Winther M, van Duijn C, Hofman A, Trip MD, Marais AD, Asztalos B, Landmesser U, Sijbrands E, Kastelein JJ, Hayden MR. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. ACTA ACUST UNITED AC 2012; 6:54-62. [PMID: 23243195 DOI: 10.1161/circgenetics.111.962613] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Endothelial lipase is a phospholipase with activity against high-density lipoprotein. Although a small number of mutations in LIPG have been described, the role of LIPG in protection against atherosclerosis is unclear. METHODS AND RESULTS We identified 8 loss-of-function (LOF) mutations in LIPG in individuals with high-density lipoprotein cholesterol. Functional analysis confirmed that most rare mutations abolish lipase activity in vitro, indicating complete LOF, whereas 2 more common mutations N396S and R476W reduce activity by ≈50%, indicating partial LOF and implying ≈50% and ≈75% remaining endothelial lipase function in heterozygous complete LOF and partial LOF mutation carriers, respectively. complete LOF mutation carriers had significantly higher plasma high-density lipoprotein cholesterol levels compared with partial LOF mutation carriers. Apolipoprotein B-depleted serum from complete LOF carriers showed significantly enhanced cholesterol efflux acceptor capacity, whereas only trends were observed in partial LOF carriers. Carriers of LIPG mutations exhibited trends toward reduced coronary artery disease in 4 independent cohorts (meta-analysis odds ratio, 0.7; P=0.04). CONCLUSIONS Our data suggest that the impact of LIPG mutations is directly related to their effect on endothelial lipase function and support that antagonism of endothelial lipase function improves cardioprotection.
Collapse
|
13
|
Basu D, Lei X, Josekutty J, Hussain MM, Jin W. Measurement of the phospholipase activity of endothelial lipase in mouse plasma. J Lipid Res 2012; 54:282-9. [PMID: 23103358 DOI: 10.1194/jlr.d031112] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Endothelial lipase (EL) is a major negative regulator of plasma HDL levels in mice, rabbits, and most probably, humans. Although this regulatory function is critically dependent on EL's hydrolysis of HDL phospholipids, as yet there is no phospholipase assay specific for EL in plasma. We developed such an assay for the mouse enzyme using a commercially available phospholipid-like fluorescent substrate in combination with an EL neutralizing antibody. The specificity of the assay was established using EL knockout mice and its utility demonstrated by detection of an increase in plasma EL phospholipase activity following exposure of wild-type mice to lipopolysaccharide. The assay revealed that murine pre-heparin plasma does not contain measurable EL activity, indicating that the hydrolysis of HDL phospholipids by EL in vivo likely occurs on the cell surface.
Collapse
Affiliation(s)
- Debapriya Basu
- Department of Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | | | | | | | | |
Collapse
|
14
|
O'Connell DP, LeBlanc DF, Cromley D, Billheimer J, Rader DJ, Bachovchin WW. Design and synthesis of boronic acid inhibitors of endothelial lipase. Bioorg Med Chem Lett 2011; 22:1397-401. [PMID: 22225633 DOI: 10.1016/j.bmcl.2011.12.043] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2011] [Revised: 12/06/2011] [Accepted: 12/08/2011] [Indexed: 10/14/2022]
Abstract
Endothelial lipase (EL) and lipoprotein lipase (LPL) are homologous lipases that act on plasma lipoproteins. EL is predominantly a phospholipase and appears to be a key regulator of plasma HDL-C. LPL is mainly a triglyceride lipase regulating (V)LDL levels. The existing biological data indicate that inhibitors selective for EL over LPL should have anti-atherogenic activity, mainly through increasing plasma HDL-C levels. We report here the synthesis of alkyl, aryl, or acyl-substituted phenylboronic acids that inhibit EL. Many of the inhibitors evaluated proved to be nearly equally potent against both EL and LPL, but several exhibited moderate to good selectivity for EL.
Collapse
Affiliation(s)
- Daniel P O'Connell
- Tufts University School of Medicine, Department of Biochemistry, 136 Harrison Ave., Boston, MA 02111, United States
| | | | | | | | | | | |
Collapse
|
15
|
Lam V, Henault M, Khougaz K, Fortin LJ, Ouellet M, Melnyk R, Partridge A. Resorufin Butyrate as a Soluble and Monomeric High-Throughput Substrate for a Triglyceride Lipase. ACTA ACUST UNITED AC 2011; 17:245-51. [DOI: 10.1177/1087057111422944] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Triglyceride lipases such as lipoprotein lipase, endothelial lipase, and hepatic lipase play key roles in controlling the levels of plasma lipoprotein. Accordingly, small-molecule modulation of these species could alter patient lipid profiles with corresponding health effects. Screening of these enzymes for small-molecule therapeutics has historically involved the use of lipid-based particles to mimic native substrates. However, particle-based artifacts can complicate the discovery of therapeutic molecules. As a simplifying solution, the authors sought to develop an approach involving a soluble and monomeric lipase substrate. Using purified bovine lipoprotein lipase as a model system, they show that the hydrolysis of resorufin butyrate can be fluorescently monitored to give a robust assay (Z′ > 0.8). Critically, using parallel approaches, they show that resorufin butyrate is soluble and monomeric under assay conditions. The presented assay should be useful as a simple and inexpensive primary or secondary screen for the discovery of therapeutic lipase modulators.
Collapse
Affiliation(s)
- Vincent Lam
- Department of In Vitro Sciences, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
| | - Martin Henault
- Department of In Vitro Sciences, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
| | - Karine Khougaz
- Department of Basic Pharmaceutical Sciences, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
| | - Louis-Jacques Fortin
- Department of In Vitro Sciences, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
| | - Marc Ouellet
- Department of In Vitro Sciences, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
| | - Roman Melnyk
- Department of Program Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
| | | |
Collapse
|
16
|
Tam J, Henault M, Li L, Wang Z, Partridge AW, Melnyk RA. An activity-based probe for high-throughput measurements of triacylglycerol lipases. Anal Biochem 2011; 414:254-60. [DOI: 10.1016/j.ab.2011.03.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2011] [Revised: 03/03/2011] [Accepted: 03/05/2011] [Indexed: 01/18/2023]
|
17
|
Darrow AL, Olson MW, Xin H, Burke SL, Smith C, Schalk-Hihi C, Williams R, Bayoumy SS, Deckman IC, Todd MJ, Damiano BP, Connelly MA. A novel fluorogenic substrate for the measurement of endothelial lipase activity. J Lipid Res 2011; 52:374-82. [PMID: 21062953 DOI: 10.1194/jlr.d007971] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Endothelial lipase (EL) is a phospholipase A1 (PLA1) enzyme that hydrolyzes phospholipids at the sn-1 position to produce lysophospholipids and free fatty acids. Measurement of the PLA1 activity of EL is usually accomplished by the use of substrates that are also hydrolyzed by lipases in other subfamilies such as PLA2 enzymes. In order to distinguish PLA1 activity of EL from PLA2 enzymatic activity in cell-based assays, cell supernatants, and other nonhomogeneous systems, a novel fluorogenic substrate with selectivity toward PLA1 hydrolysis was conceived and characterized. This substrate was preferred by PLA1 enzymes, such as EL and hepatic lipase, and was cleaved with much lower efficiency by lipases that exhibit primarily triglyceride lipase activity, such as LPL or a lipase with PLA2 activity. The phospholipase activity detected by the PLA1 substrate could be inhibited with the small molecule esterase inhibitor ebelactone B. Furthermore, the PLA1 substrate was able to detect EL activity in human umbilical vein endothelial cells in a cell-based assay. This substrate is a useful reagent for identifying modulators of PLA1 enzymes, such as EL, and aiding in characterizing their mechanisms of action.
Collapse
Affiliation(s)
- Andrew L Darrow
- Pharmaceutical Research and Development, Johnson & Johnson LLC , Spring House, PA 19477-0776, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Basu D, Manjur J, Jin W. Determination of lipoprotein lipase activity using a novel fluorescent lipase assay. J Lipid Res 2011; 52:826-32. [PMID: 21270098 DOI: 10.1194/jlr.d010744] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
A novel, real-time, homogeneous fluorogenic lipoprotein lipase (LPL) assay was developed using a commercially available substrate, the EnzChek lipase substrate, which is solubilized in Zwittergent. The triglyceride analog substrate does not fluoresce, owing to apposition of fluorescent and fluorescent quenching groups at the sn-1 and sn-2 positions, respectively, fluorescence becoming unquenched upon release of the sn-1 BODIPY FA derivative following hydrolysis. Increase in fluorescence intensity at 37°C was proportional to LPL concentration. The assay was more sensitive than a similar assay using 1,2-O-dilauryl-rac-glycero-3-glutaric acid-(6-methylresorufin ester) and was validated in biological samples, including determination of LPL-specific activity in postheparin mouse plasma. The simplicity and reproducibility of the assay make it ideal for in vitro, high-throughput screening for inhibitors and activators of LPL, thus expediting discovery of drugs of potential clinical value.
Collapse
Affiliation(s)
- Debapriya Basu
- Department of Cell Biology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
| | | | | |
Collapse
|
19
|
Kojima Y, Ishida T, Sun L, Yasuda T, Toh R, Rikitake Y, Fukuda A, Kume N, Koshiyama H, Taniguchi A, Hirata KI. Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo. Cardiovasc Res 2010; 87:385-93. [PMID: 20045866 DOI: 10.1093/cvr/cvp419] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
AIMS In addition to their cholesterol-lowering effect, statins increase high-density lipoprotein cholesterol (HDL-C) levels. Endothelial lipase (EL) is a regulator of plasma HDL-C levels. In the present study, the effects of statins on EL expression were investigated. METHODS AND RESULTS The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin suppressed basal and cytokine-treated EL expression in endothelial cells. Concomitant treatment with mevalonate or geranylgeranyl pyrophosphate completely reversed the inhibitory effect of pitavastatin, suggesting that geranylgeranylated proteins are involved in the inhibition of EL expression by statins. Inhibition of RhoA activity by overexpression of a dominant-negative mutant of RhoA or a Rho kinase inhibitor decreased EL levels. Pitavastatin reduced phospholipase activities of endothelial cells, and concomitant treatment with mevalonate reversed its inhibitory effect. Pitavastatin reduced RhoA activity and EL expression in mouse tissues. Furthermore, plasma EL concentrations in human subjects were measured by enzyme-linked immunosorbent assays. Plasma EL levels were negatively associated with plasma HDL levels in 237 patients with cardiovascular diseases, and pitavastatin treatment reduced plasma EL levels and increased HDL-C levels in 48 patients with hypercholesterolaemia. CONCLUSION These findings suggest that statins can reduce EL expression in vitro and in vivo via inhibition of RhoA activity. The inhibition of EL expression in the vessel wall may contribute to the anti-atherogenic effects of statins.
Collapse
Affiliation(s)
- Yoko Kojima
- Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Rohand T, Lycoops J, Smout S, Braeken E, Sliwa M, Van der Auweraer M, Dehaen W, De Borggraeve WM, Boens N. Photophysics of 3,5-diphenoxy substituted BODIPY dyes in solution. Photochem Photobiol Sci 2007; 6:1061-6. [PMID: 17914479 DOI: 10.1039/b705921c] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We have prepared two fluorescent dyes derived from 8-(4-tolyl)-4,4-difluoro-4-bora-3a,4a-diaza-s-indacene with phenoxy and (o-bromo)phenoxy substituents at the 3,5-positions by a novel nucleophilic substitution reaction of the corresponding 3,5-dichloroBODIPY analogue. UV-vis absorption, steady-state and time-resolved fluorimetry have been used to investigate their solvent-dependent photophysical properties. The two BODIPY derivatives show narrow absorption and emission bands and display small Stokes shifts. The substituents at the 3,5-positions (phenoxy in 1 and o-bromophenoxy in 2) have a minor effect on the fluorescence quantum yields (0.16-0.40 for 1, 0.17-0.44 for 2) and lifetimes (1.09-2.51 ns for 1, 1.11-2.78 ns for 2). For both compounds, the fluorescence rate constant equals (1.5 +/- 0.1) x 10(8) s(-1).
Collapse
Affiliation(s)
- Taoufik Rohand
- Department of Chemistry and Institute for Nanoscale Physics and Chemistry, Katholieke Universiteit Leuven, Celestijnenlaan 200f - bus 02404, 3001, Leuven, Belgium
| | | | | | | | | | | | | | | | | |
Collapse
|